Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a component of the CRL4 E3 ligase complex. This compound serves as a key element in PROTAC (proteolysis-targeting chimera) technology, facilitating targeted protein degradation. Its biological activity supports research in protein regulation, cellular signaling, and therapeutic strategies for disease intervention. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C6-NHBoc is an E3 ligase ligand-linker conjugate that combines the Thalidomide derivative with a hexyl linker suitable for use in PROTAC technology. This compound functions primarily by targeting cereblon, facilitating the degradation of specific proteins through induced ubiquitination. It is valuable for research applications involving targeted protein degradation and the modulation of signaling pathways associated with various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-Propargyl is an E3 ligase ligand-linker conjugate that features the cereblon ligand derived from Thalidomide, along with a PEG4 linker designed for PROTAC technology. This compound serves as a versatile click chemistry reagent due to its alkyne functionality, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique properties facilitate targeted protein degradation and make it valuable for research applications in drug discovery and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through the PROTAC technology, promoting the recruitment of E3 ligases to specific substrates. Its key biological activity makes it a valuable tool for research in cellular regulation, protein homeostasis, and potential therapeutic applications in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG3-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation via the PROTAC (proteolysis-targeting chimera) technology, promoting ubiquitination and subsequent proteasomal degradation of specific proteins. Thalidomide-5-PEG3-NH2 is valuable for research applications investigating protein homeostasis and therapeutic strategies in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG3-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol linker. This compound is designed for use in proteolysis-targeting chimera (PROTAC) technology, facilitating the selective degradation of target proteins. By efficiently engaging E3 ligases, Thalidomide-PEG3-NH2 serves as a valuable tool in drug development and biochemical research focused on targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate targeting cereblon, a key component in the ubiquitin-proteasome pathway. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enabling researchers to manipulate cellular protein levels with high specificity. Its unique linker structure enhances the conjugate’s stability and efficacy in various biological applications, making it a valuable tool for studying protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C7-NH2 is an E3 ligase ligand-linker conjugate featuring a thalidomide-derived cereblon ligand and a functionalized linker designed for use in PROTAC technology. This compound exhibits biological activity by recruiting target proteins for ubiquitination and subsequent proteasomal degradation. It is a valuable tool for researchers exploring targeted protein degradation and the modulation of protein levels within cellular systems. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C4-NH2 TFA is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand attached to a linker. This compound serves as a critical component in the development of PROTAC BRD2/BRD4 degrader-1, which effectively degrades the BET proteins BRD4 and BRD2. Its utility in this context highlights its potential in targeted protein degradation research and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C3-NH2 is an E3 ligase ligand-linker conjugate that features a cereblon ligand derived from thalidomide, combined with a linker suitable for PROTAC technology. This compound facilitates targeted protein degradation by promoting the ubiquitination of specific substrates through interactions with the ubiquitin-proteasome system. It is widely utilized in research applications focused on the development and optimization of PROTACs for therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the formation of PROTAC iRucaparib-AP6, a highly specific degrader of PARP1, by linking to the target protein via a linker. Its primary mechanism involves enhancing protein degradation pathways, offering significant potential in targeted protein knockdown studies and cancer research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C8-NH2 hydrochloride functions as an E3 ligase ligand-linker conjugate, incorporating the Thalidomide-derived cereblon ligand along with a suitable linker. This compound is instrumental in the development of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation in research applications. Its structural features facilitate selective binding to E3 ligases, making it a valuable tool in drug discovery and cellular function studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG3-NH2 is a synthetic E3 ligase ligand-linker conjugate featuring a thalidomide-derived cereblon ligand. This compound is designed for use in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation through its interaction with E3 ligases. It provides a valuable tool for researchers investigating protein turnover and therapeutic interventions in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-C2-NH2 is an engineered E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand linked to a two-unit PEG moiety. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation by recruiting E3 ligases. It is suitable for investigations into protein homeostasis, signaling pathways, and therapeutic applications in cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG-C2-NH2 is an E3 ligase ligand-linker conjugate designed to target cereblon, a substrate recognition component of the ubiquitin-proteasome system. This compound facilitates protein degradation via PROTAC technology, enabling the selective modulation of protein levels within cells. Its application is particularly relevant in studies of gene regulation and targeted therapy development in various diseases, including cancer. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-4-O-C6-NH2 TFA is a synthetic E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound plays a critical role in the PROTAC dTAG-13, facilitating the selective degradation of FKBP12F36V and BET proteins. Its unique structural features allow for efficient recruitment of E3 ligases, making it a valuable tool in cellular studies of protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 TFA is an E3 ligase ligand-linker conjugate that contains the thalidomide-derived cereblon ligand and a C5 amino linker, facilitating targeted protein degradation via PROTAC technology. This reagent is designed for research applications involving the modulation of protein homeostasis and the therapeutic potential of targeted protein degradation strategies. Its unique structure enables the selective recruitment of E3 ligases, thus enhancing the efficacy of drug discovery and development processes involving the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-O-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate targeting cereblon. This compound incorporates a Thalidomide-based ligand along with a linker designed for use in PROTAC technology, enabling selective protein degradation. Its unique structure allows for the potential modulation of cellular pathways, making it particularly valuable in drug discovery and development research. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG4-MS is an E3 ligase ligand-linker conjugate, featuring Thalidomide as a cereblon ligand. It is designed to facilitate targeted protein degradation through the recruitment of E3 ubiquitin ligases. This compound is primarily utilized in the development of PROTACs targeting BCL-XL, enabling effective degradation of specific proteins within cancer research and other cellular studies. -
E3 ligase ligand-linker conjugate
Thalidomide-4-O-C6-NH2 is an engineered E3 ligase ligand-linker conjugate that features a cereblon ligand derived from Thalidomide. This compound serves as a critical component in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation. Its unique structure supports research into molecular modulators and therapeutic interventions in diseases where protein homeostasis is disrupted. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate designed to target the cereblon E3 ligase. This compound utilizes a PEG-based linker, enabling its application in PROTAC (Proteolysis Targeting Chimera) technology for targeted protein degradation. Thalidomide-PEG2-NH2 facilitates the selective modulation of protein levels, providing a valuable tool for research in cellular signaling, cancer biology, and pharmacological studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C6-NH2 serves as an E3 ligase ligand-linker conjugate, featuring a thalidomide-based cereblon ligand with an integrated linker. This compound is utilized in the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation pathways. Its unique structure allows for selective degradation of specific proteins, making it valuable in cancer research and other therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that integrates a Thalidomide-derived cereblon ligand with a PEG4 linker, facilitating the targeted degradation of proteins via PROTAC technology. This compound enables selective modulation of protein levels in cellular systems, making it a valuable tool for drug development and research into targeted protein degradation mechanisms. Its applications extend to studying E3 ligase interactions and enhancing the effectiveness of therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-O-C8-NH2 is an E3 ligase ligand-linker conjugate integrating a Thalidomide-derived cereblon ligand with a C8 linker, designed for use in PROTAC (proteolysis-targeting chimera) applications. This compound facilitates targeted protein degradation by harnessing the ubiquitin-proteasome system, thereby enabling the selective modulation of protein levels within cellular environments. Its primary applications lie in the development of novel therapeutics and research in cellular pathways regulated by ubiquitination. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C3-acid is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a component of the E3 ubiquitin ligase complex. This compound is utilized in PROTAC (Proteolysis Targeting Chimeras) technology to facilitate targeted degradation of proteins, enhancing the study of protein homeostasis and therapeutic interventions in various diseases. Its unique structure allows for the development of novel bioconjugates for offsetting pathological protein accumulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a hexylamine linker. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, facilitating targeted protein degradation by engaging specific E3 ligases. Thalidomide-NH-C6-NH2 is primarily utilized in research applications aimed at studying protein turnover and modulating cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-Piperidine is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a key component in the ubiquitin-proteasome system. This compound incorporates a Thalidomide-based ligand and a piperazine-piperidine linker, making it suitable for use in PROTAC (proteolysis-targeting chimeras) technology. Its design facilitates targeted degradation of specific proteins, providing valuable insight into protein regulation and function in various biological contexts. Thalidomide-Piperazine-Piperidine is ideal for research applications involving targeted protein degradation and cellular signaling pathways. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-PEG2-C2-NH2 serves as an E3 ligase ligand-linker conjugate, playing a critical role in the modulation of immune responses. This compound exhibits immunomodulatory activity, making it relevant for cancer research and therapeutic applications. Its unique design allows for specific targeting of E3 ligases, facilitating the study of protein degradation pathways in cancer biology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that features thalidomide as a cereblon ligand, combined with a five-carbon amine linker. This compound is designed for applications in Proteolysis Targeting Chimeras (PROTAC) technology, facilitating targeted protein degradation. Its mechanism involves the binding of the conjugate to E3 ligases, enabling the selective degradation of target proteins, which is useful in drug discovery and development for various therapeutic applications. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-C2-PEG3-OH is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand paired with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeric) strategies, specifically for the degradation of BCL-XL through targeted ubiquitination. Its capabilities enable precise modulation of protein levels, facilitating research in targeted protein degradation and its applications in cancer therapy. -
HCK/BTK PROTAC Degrader
DFCI-002-06 is an orally active PROTAC degrader targeting both HCK and BTK, demonstrating DC₅₀ values of 1.3 nM and 4.5 nM, respectively. This compound exhibits superior anti-tumor activity compared to a dual-target inhibitor, promoting apoptosis in cancer cells, particularly in MYD88 mutant B-cell malignancies. DFCI-002-06 serves as a valuable tool for researching mechanisms underlying these specific cancer types. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C4-NH-Boc is an E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a specialized linker designed for PROTAC technology. This compound facilitates the targeted degradation of proteins by harnessing the ubiquitin-proteasome system, making it a valuable tool for researchers investigating protein turnover and cellular regulation. Its applications extend to drug discovery, developmental biology, and therapeutics, where selective protein modulation is critical. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine-O-azetidine-boc is a conjugate designed as an E3 ubiquitin ligase ligand-linker. This compound facilitates the synthesis of complete PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation in various biological research applications. It serves as a valuable tool for studying protein function and modulation, particularly in therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a designated linker for use in PROTAC technology. This compound is designed to facilitate targeted protein degradation by harnessing the cellular ubiquitin-proteasome system. Its applications extend to studies in drug discovery and cellular signaling, enabling researchers to investigate the modulation of protein levels with precision. -
Molecular Glue GSPT1 Degrader
TD-522 is a potent and selective molecular glue targeting GSPT1 for degradation, exhibiting a DC50 of 0.269 nM. This compound demonstrates significant anti-proliferative activity and induces apoptosis in acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) cell lines. Additionally, TD-522 effectively suppresses tumor growth in a TMD-8 xenograft model. It is applicable for research focused on AML and DLBCL. -
PROTAC BRD4 Degrader
PROTAC BRD4 Degrader-17 is a potent protein degrader targeting bromodomain-containing protein 4 (BRD4). It exhibits IC50 values of 29.54 nM for BRD4 (BD1) and 3.82 nM for BRD4 (BD2). This compound effectively inhibits G2/M cell cycle progression, leading to decreased expression of Cyclin B1, and significantly induces apoptosis in MV-4-11 cells. PROTAC BRD4 Degrader-17 is valuable for research applications focused on cancer cell biology and the development of targeted degraders in therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-C-PIP-C-boc is an E3 ligase ligand-linker conjugate that incorporates Thalidomide, serving as a recruiter for the cereblon (CRBN) protein. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by acting as a critical intermediate for the synthesis of complete PROTAC molecules. Its utility in research includes applications in targeted protein degradation strategies, providing a platform for innovative therapeutic development. -
Ligands for E3 Ligase
Thalidomide-NH-(CH2)3-NH-Boc is a Boc-modified thalidomide that serves as a ligand for cereblon (CRBN), facilitating the recruitment of CRBN protein within cellular systems. The Boc protecting group can be removed under acidic conditions, enabling its use in the synthesis of PROTAC (proteolysis-targeting chimeras) molecules. This compound plays a crucial role as an intermediate for synthesizing CRBN-based designed PROTACs, particularly those targeting 11β-substituted estradiol, making it valuable for research in targeted protein degradation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C3-NH2 is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from Thalidomide with a specialized linker for PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates targeted protein degradation by recruiting specific substrates to the ubiquitin-proteasome system. Thalidomide-O-C3-NH2 is instrumental for research applications in protein regulation and therapeutic development, particularly in understanding cellular processes and disease mechanisms. -
PROTAC EGFR Degrader
PROTAC EGFR Degrader 5 is a targeted protein degradation agent that effectively degrades the EGFRDel19 variant in HCC827 cells, exhibiting a DC50 of 34.8 nM. This compound significantly induces apoptosis and leads to G1 phase cell cycle arrest in HCC827 cells, making it a valuable tool for studying EGFR-related signaling pathways and potential therapeutic interventions in lung cancer research. -
FLT3-PROTAC Degrader
PROTAC FLT-3 degrader 4 is a CRBN-based degrader that selectively targets FLT3-ITD mutants by harnessing the ubiquitin-proteasome system for degradation. This compound demonstrates potent activity against FLT3-ITD mutant acute myeloid leukemia (AML) cells, offering a focused approach for research applications in cancer therapeutics. Its oral bioavailability positions it as a valuable tool for investigating FLT3-related signaling pathways and potential treatment strategies in AML. -
p53 Stabilizer/MDM2 PROTAC Degrader
Seldegamadlin is a selective p53 stabilizer and an MDM2 PROTAC degrader with a DC50 of 0.4 nM. It effectively inhibits the proliferation of RS4;11 cancer cells, demonstrating an IC50 of 0.3 nM, and induces cell cycle arrest at the G2/M phase while promoting apoptosis. By upregulating p53 activity, Seldegamadlin overcomes the p53-MDM2 feedback loop, making it a valuable tool for research in hematologic and solid tumors, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). -
CK1α Molecular Glue
BMS-986397 is a selective and orally active cereblon-based molecular glue degrader targeting casein kinase 1α (CK1α). This compound effectively induces apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells, positioning it as a valuable tool for research in the fields of AML and high-risk myelodysplastic syndromes (HR-MDS). Its unique mechanism offers potential for elucidating CK1α's role in these malignancies. -
CRY1 Molecular Glue Degrader
M47 is a molecular glue degrader that specifically targets Cryptochrome 1 (CRY1), promoting its degradation within the nucleus. This compound has been shown to enhance apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and prolong lifespan in p53 knockout mice. M47 serves as a valuable tool for research focused on cancer biology and the mechanisms of targeted protein degradation. -
Ligands for E3 Ligase
Thalidomide-5-OH is an E3 ligase ligand that specifically targets the cereblon (CRBN) protein. This compound facilitates the recruitment of CRBN, enabling targeted protein degradation through the formation of PROTACs (proteolysis-targeting chimeras) by linking it to another ligand. Thalidomide-5-OH is utilized in research applications focusing on targeted protein degradation and therapeutic development for various diseases. -
AR-FL/AR-V7 PROTAC Degrader
BWA-522 is an orally active PROTAC degrader that targets the full-length androgen receptor (AR-FL) and its splice variant AR-V7. By antagonizing the N-terminal domain of the androgen receptor, BWA-522 effectively suppresses downstream signaling pathways and induces apoptosis in cancer cells. Furthermore, this compound has demonstrated significant inhibition of tumor growth in LNCaP xenograft mouse models, making it a valuable tool for prostate cancer research. -
Ligands for E3 Ligase
Thalidomide-NH-CH2-COOH is a Thalidomide-derived ligand that specifically targets the cereblon (CRBN) protein, facilitating its recruitment in various biological processes. This compound serves as a crucial building block for the development of PROTACs, allowing researchers to design targeted protein degradation strategies. Its application is significant in the study of protein homeostasis and the therapeutic potential of targeted protein modulation. -
Molecular Glue
(R)-CR8 trihydrochloride is a potent inhibitor of CDK1, CDK2, CDK5, CDK7, and CDK9, functioning as a molecular glue degrader that targets cyclin K. With inhibitory activity characterized by low nanomolar IC50 values, it effectively induces apoptosis while exhibiting neuroprotective properties. This compound is suitable for research applications in cancer biology and neurodegenerative disease studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-PEG4-NHS ester is a PEG-based linker designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). It functions as a ligand for E3 ligases, facilitating targeted protein degradation. This compound is instrumental in chemical biology research aimed at exploring pathways involved in protein turnover and has applications in developing therapeutics for diseases driven by dysregulated protein levels. -
Molecular Glues
(S)-Thalidomide is the S-enantiomer of Thalidomide, functioning as a molecular glue. It exerts significant biological activities, including immunomodulation, anti-inflammation, antiangiogenesis, and pro-apoptosis. This compound induces teratogenic effects through its interaction with cereblon (CRBN), making it a valuable tool for research into cell signaling pathways and developmental biology.
